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Summary. Melanoma arising from melanocytes within
the choroid is the most frequent primary intraocular
neoplasm in adults. It is biologically distinct from
cutaneous melanoma by a very strong propensity to
metastasize the liver. Raf kinase inhibitor protein is a
member of an evolutionarily conserved group of proteins
called phosphatidylethanolamine-binding proteins. It is
an interacting partner of Raf-1 and a negative regulator
of the mitogen-activated protein kinase cascade initiated
by Raf-1. Raf kinase inhibitor protein expression is low
in many human cancers and represents an indicator of
poor prognosis and/or induction of metastasis. In the
present study, we examined the immunohistochemical
expression levels of Raf kinase inhibitor protein and
phosphorylated Raf kinase inhibitor protein in primary
uveal melanoma with and without metastasis, and
evaluated their association with other high risk
characteristics for metastasis in order to assess whether
Raf kinase inhibitor protein and phosphorylated Raf
kinase inhibitor protein can be used to predict
metastasis. A significant low expression of Raf kinase
inhibitor protein was seen in patients with metastasis but
not in patients without metastasis. The latter more
frequently had a high expression of Raf kinase inhibitor
protein. No significant difference was seen in
phosphorylated Raf kinase inhibitor protein expression
between patients with and without metastasis. Raf kinase
inhibitor protein expression is a suitable and easily
determinable marker in the primary tumour that could
predict the risk of uveal melanoma to metastasize, and
hence guide strategies for monitoring and therapy.
Key words: RKIP, pRKIP, Uveal melanoma, Immuno-
histochemistry
Introduction
Melanoma arising from melanocytes within the
choroid is the most frequent primary intraocular
neoplasm in adults. This tumour predominately occurs in
the blue-eyed, blond population of Northern European
ancestry; approximately 1 percent of malignant
melanomas occur in African-Americans (Margo and
McLean, 1984). Most studies find a higher incidence of
uveal melanoma in men than women. Sun exposure is
not a risk factor for choroidal and ciliary body
melanoma (Shah et al., 2005). It has been suggested that
most of them arise from preexisting benign nevi,
congenital melanosis oculi and oculo-dermal
melanocytosis (nevus of Ota) (Spagnolo et al., 2012).
Malignant melanoma may be located at any point in the
uveal tract, with the choroid and ciliary body being more
frequent locations than the iris. It is biologically distinct
from cutaneous melanoma by a very strong propensity to
metastasize the liver. Indeed, up to 50% of patients with
primary uveal melanoma develop distant metastasis, the
liver being involved in up to 90% of individuals and the
median survival being 4-5 months. Patients’ survival has
not been improved despite new diagnostic and
therapeutic modalities, which have led to a better eye
preservation rate only (Singh and Topham, 2003). Uveal
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melanoma also differs from cutaneous melanoma in the
presence of chromosomal aberrations, with frequent loss
of chromosome 3 (Prescher et al., 1996), which is also a
prognostic indicator. Currently, malignant melanoma of
the uvea are divided into three cell types: 1) spindle cell;
2) epithelioid cell; and 3) mixed cell type (McLean et al.,
1983).
RKIP (Raf kinase inhibitor protein) is a member of
an evolutionarily conserved group of proteins called
PEBP1 (phosphatidylethanolamine-binding protein 1). It
is an interacting partner of Raf-1 and a negative
regulator of the mitogen-activated protein kinase
(MAPK) cascade initiated by Raf-1 (Yeung et al., 1999).
Subsequently, RKIP was shown also to suppress the
activation of the nuclear factor kappa B (NFκB)
transcription factor by blocking the inactivation of the
inhibitor of NFκB, IκB (Yeung et al., 2001). Both
pathways play an important role in cancer and invasion
(Reddy et al., 2003; Greten and Karin, 2004). In
mammals, RKIP is also a negative regulator of G-protein
coupled receptors (GPCRs) by inhibiting G-protein
coupled receptor kinase (GRK-2) (Lorenz et al., 2003).
Actually, RKIP has been implicated in various
intracellular signalling pathways that control cell growth
(Akaishi et al., 2006), motility (Al-Mulla et al., 2010),
epithelial to mesenchymal transition (EMT) (Baritaki et
al., 2009) and differentiation (Hellmann et al., 2010).
The RKIP is a conserved cytosolic protein with wide
tissue expression and does not share significant
homology with other kinase inhibitors (Serre et al.,
2001). Aberrant RKIP expression may play a critical role
in the malignant process considering that RKIP is a
metastasis suppressor gene product. Studies have shown
that overexpression of RKIP inhibited metastasis and
down-regulation of RKIP increases the metastatic
potential. In mice, RKIP that was exogenously expressed
led to a decreased level of metastasis and invasion in
transformed metastatic cells (Fu et al., 2003). 
More recently, sorafenib, (Buzzacco et al., 2012) a
multi-kinase inhibitor, targeting Raf kinase and VEGFR,
has proven to have therapeutic a effect in uveal
melanoma, thus heralding a new era of molecular
targeting therapy and reinforcing the utility of blocking
Ras/MAPK signals in the treatment of this tumor. The
inhibitory activity of RKIP on the Raf-1/MEK/ERK
pathway is, at least in part, regulated by protein kinase C
(PKC) induced phosphorylation of RKIP at serine 153
(Corbit et al., 2003). Mutant RKIP that has serine 153
substituted with valine failed to associate with Raf-1 and
was not phosphorylated following PKC stimulation. It
has also been reported that phosphorylated Raf kinase
inhibitor protein (pRKIP) binds to GRK-2 and, thus,
inhibits GRK-2-mediated phosphorylation of G protein
coupled receptors (GPCRs) resulting in the inhibition of
receptor internalization and cell signalling integrity
(Lorenz et al., 2003). The resultant inhibition of receptor
internalization has been predicted to promote cell growth
and survival by maintaining appropriate extracellular
signaling stimulation (Lorenz et al., 2003). 
In the present study, we examined the expression levels
of RKIP and pRKIP in primary uveal melanoma with
and without metastasis, and evaluated their association
with other high risk characteristics for metastasis in
order to assess if RKIP and pRKIP can be used to predict
metastasis.
Materials and methods
The authors performed a retrospective analysis of
clinical records and formalin-fixed, paraffin-embedded
(FFPE) tissue specimens of all cases of primary
choroidal and/or ciliary body melanoma treated by
primary enucleation at the Eye Clinic, University of
Catania, Catania, Italy during the eight years up to
October 2012. Enucleations were performed in the case
of tumours not suitable for radiotherapy procedures,
such as plaque brachytherapy or proton beam
radiotherapy. Cases were excluded if the paraffin blocks
containing the tumour could not be located for the
preparation of additional slides for the immunohisto-
chemical staining study, representative tumour tissue
was not present in the paraffin blocks, if the tumour was
completely necrotic, or the tumour had been treated
previously by a method such as plaque radiotherapy or
proton beam radiotherapy, which might have altered the
histopathologic features and immunoreactivity of the
tumours. Formalin-fixed and paraffin-embedded tissue
specimens were obtained from the surgical pathology
files at the Anatomic Pathology, Department G.F.
Ingrassia, University of Catania, Catania, Italy. From
formalin-fixed and paraffin-embedded tissue specimens
multiple sections (at least 5) were obtained. Due to the
retrospective nature of the study, no written informed
consent from patients was obtained. The research
protocols were approved by the Local Medical Ethical
Committee (University of Catania) and conformed to the
ethical guidelines of the Declaration of Helsinki. In
order to use uniform criteria, all histological slides were
evaluated by two pathologists (RC and LP). However,
there is no general consensus among ophthalmic
pathologists regarding the number of spindle and
epithelioid cells required for the diagnosis of mixed cell
type melanoma. Tumors with a few epithelioid cells (3
to 5 percent) were classified as mixed. The study
consisted of 32 uveal melanomas without metastasis and
12 uveal melanomas with metastasis. From clinical
charts the following data were collected: size and
location of the tumour evaluated through
ophthalmoscopy and A and B scan ultrasonography The
presence of metastasis was assessed using standard
modalities, including physical examination, liver
ultrasound and total body computed tomography.
Immunohistochemistry
Sections were processed as previously described
(Leonardi et al., 2012). Briefly, they were incubated for
30 min in 0.3% H2O2/methanol to quench endogenous
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peroxidase activity then rinsed for 20 min with
phosphate-buffered saline (PBS; Bio-Optica, Milan,
Italy). The sections were heated (5 min × 3) in capped
polypropylene slide-holders with citrate buffer (10 mM
citric acid, 0.05% Tween 20, pH 6.0; Bio-Optica, Milan,
Italy), using a microwave oven (750 W) to unmask
antigenic sites. The blocking step performed before
application of the primary antibody with goat serum
(Vector Laboratories, Burlingame, CA, USA), 1:20 work
dilution in PBS-T, 1 h in a moist chamber. Then, the
sections were incubated overnight at 4 °C with rabbit
polyclonal antibodies RKIP and pRKIP (FL-187: sc-
28837; and hSer 153: sc-32626 for RKIP and pRKIP,
respectively, Santa Cruz Biotechnology, Milan, Italy)
were used at a dilution 1:200. The secondary antibody,
biotinylated anti-mouse antibody was applied for 30 min
at room temperature, followed by the avidin-biotin-
peroxidase complex (Vector Laboratories, Burlingame,
CA, USA) for a further 30 min at room temperature. The
immunoreaction was visualized by incubating the
sections for 4 min in a 0.1% 3,3'-diaminobenzidine
(DAB) and 0.02% hydrogen peroxide solution (DAB
substrate kit, Vector Laboratories, CA, USA). The
sections were lightly counterstained with Mayer’s
hematoxylin (Histolab Products AB, Göteborg, Sweden)
mounted in GVA mountant (Zymed Laboratories, San
Francisco, CA, USA) and observed with a Zeiss
Axioplan light microscope (Carl Zeiss, Oberkochen,
Germany).
Evaluation of immunohistochemistry
Immunostained slides were separately evaluated by
two pathologists (RC and LP), who were blinded to
patient identity, clinical status and group identification,
using a light microscope.
The RKIP and pRKIP-staining status was identified
as either negative or positive. Immunohistochemistry
positive staining was defined as the presence of brown
chromogen detection on the edge of the hematoxylin-
stained cell nucleus, distributed within the cytoplasm or
in the membrane. Stain intensity and the proportion of
immunopositive cells were assessed by light microscopy.
Intensity of staining (IS) was graded on a scale of 0-3,
according to the following assessment: no detectable
staining = 0, weak staining = 1, moderate staining = 2,
strong staining = 3, as described previously (Allegra et
al., 2013). The percentage of RKIP and pRKIP
immunopositive cells (Extent Score (ES)) was
independently evaluated by two investigators and scored
as a percentage of the final number of 100 cells in five
categories: <5% (0); 5-30% (+); 31-50% (++); 51-75%
(+++), and >75% (++++). Counting was performed at
200×magnification. The staining intensity was
multiplied by the percentage of positive cells to obtain
the intensity reactivity score (IRS). Positive and negative
controls were performed to test the specific reaction of
primary antibodies used in this study at a protein level.
Positive controls consisted of sections of rat liver. For
negative controls, testing sections of uveal melanoma
were treated with normal rabbit serum instead of the
specific antibodies. 
Statistical analysis
Non parametric comparison of the median values of
all parameters in patients without metastasis and with
metastasis was performed by Kolmogorov-Smirnov test
or chi-square test. Agreement among observers was
tested by Cohen K. Considering the median of the values
of RKIP and pRKIP detected in all patients, each case
has been classified into two categories (high and low)
that expressed RKIP and pRKIP higher/equal or lower
than the median value. Univariate and multivariate
analysis were based on a Cox proportional hazards
regression model (time free from metastasis as
outcome); this model included gender, age, melanoma
location (choroid or ciliary body), temporal or nasal
location, cell type (epithelioid, spindle cells or mixed),
echographic parameters (height, greatest and minor
diameters, internal reflectivity), and value of RKIP and
pRKIP expression. All predictors that had a P value
<0.15 (cut off) in the univariate analysis were included
in the multivariate analysis. Survival analysis according
to RKIP and pRKIP expression levels was performed by
Kaplan-Meyer test; survival rates were compared by log-
rank (Mantel-Cox) test. P values <0.05 were considered
as statistically significant.
Results 
Clinicopathological characteristics of uveal melanomas
This study included a total of 44 patients, 22 men
and 22 women, with uveal melanoma. At the time of
diagnosis, median age was 64 years (range 29 to 85
years). The clinicopathological parameters are listed in
tables 1, 2 and 3. Of the tumours, 31 (70.4%) were
located in the choroid and 13 (29.6%) tumours involved
the choroid and ciliary body. There was only one case
with extrascleral extension that was evaluated visually
during surgery, with ultrasonography and tomography
and confirmed histologically. Histologically, 26 (59.1%)
tumours were classified as mixed; 12 (27.3%), as spindle
cells; 6 (13.6%), as epithelioid cells, respectively.
Pathological T stage was T1a (pT1a) for 1 (2.3%)
tumour, 22 (50%) were pT2a, 10 (22.7%) were pT2b, 1
(2.3%) was pT2d, 7 (15.9%) were pT3a, and 3 (6.8%)
were pT3b. Liver involvement was detected in 12 cases
(27.3%). The median follow-up period was 41 months
(range: 0-112 months). The group of patients (n=32)
affected by uveal melanoma without metastasis included
17 males and 15 females, with an age ranging between
29 and 85 years (median 63 yrs). The group of patients
(n=12) affected by metastatic uveal melanoma included
5 males and 7 females, with an age ranging between 48
and 76 years (median 67 yrs). During the follow-up
period, 6 of them died due to disease progression.
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Between the two groups (patients with or without
metastasis), a significant difference was seen in cell type
(p=0.025), disease free survival (p=0.006), and RKIP
(p<0.001). Median follow-up was greater in the group
without metastasis (55 vs 38 months) (table 3).
Correlations between RKIP and pRKIP expression and
clinicopathological factors in uveal melanomas
In the whole group (n=44) median RKIP value was 8
and median pRKIP value was 5. RKIP expression was
low in 12 (27.2%) tumours (Fig. 1a), and high in 32
(72.7%) tumours (Fig. 1b). pRKIP expression was low in
22 (50%) tumours (Fig. 2a), and high in 22 (50%)
tumours (Fig. 2b). No expression of pRKIP was
identified for in non-tumoral ocular tissue. Interobserver
agreement measured as kappa coefficient was 0.938
(excellent).
A significantly low expression of RKIP was seen in
patients with metastasis (10/12, 83.3%), but not in
patients without metastasis (2/32, 6.3%) (chi-square,
p<0.001); this latter more frequently had a high
expression of RKIP (30/32, 93.7%). No significant
difference was seen in pRKIP expression between
patients with and without metastasis (Table 4).
Factors related to the presence of metastasis at
univariate analysis on a Cox proportional hazards
regression model were: tumour greater diameter
(p=0.061), pT stage (p=0.091), cell type (p=0.008), and
RKIP level (p<0.001); at multivariate analysis only
RKIP level (p<0.001) and pT stage (p=0.014) were
significant. No correlation was found between
histological type and both RKIP and pRKIP expression
(Spearman).
Figure 3 shows the results of Kaplan-Meier survival
analyses in patients with uveal melanomas with low and
high RKIP and pRKIP expression. The survival times
free from metastasis (SE, with 95% CI) estimated were
respectively: 21.9 (6.9) (CI: 8.4 to 35.3) and 105.3 (4.5)
(CI: 96.5 to 114.2) for RKIP; and 80.2 (9.7) (CI: 61.1 to
99.3) and 58.2 (5.8) (CI: 47 to 69.5) for pRKIP
The log-rank test showed a significant difference
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Table 1. Demographics, tumour parameters, disease free time, follow-up and RKIP and pRKIP expression in primary uveal melanoma without
metastasis.
Sex Age Location Thickness Largest Cell Extrascleral Pathological DFS Follow-up RKIP pRKIP
(yrs) (mm) diameter (mm) type extension T stage (months) (months)
IS ES IRS IS ES IRS
M 52 choroid 7.9 13.3 spindle N pT2a 95 95 2 4 8 H 0 0 0 L
F 29 choroid 14.2 16.2 mixed N pT2a 90 90 3 3 9 H 0 0 0 L
M 54 choroid 9.2 17 spindle N pT2a 112 112 3 4 12 H 0 0 0 L
F 30 choroid/cil.body 12.05 9.2 spindle N pT2b 72 72 3 4 12 H 0 0 0 L
F 83 choroid/cil.body 6.84 14.2 mixed N pT2b 74 74 2 4 8 H 0 0 0 L
F 55 choroid 9.8 13.9 spindle N pT2a 73 73 3 3 9 H 2 4 8 H
M 74 choroid/cil.body 10.04 16.1 spindle N pT2b 72 72 2 4 8 H 3 3 9 H
M 80 choroid 6.04 10.5 mixed N pT1a 68 68 3 3 9 H 3 4 12 H
M 68 choroid 12.8 20.1 mixed N pT2a 68 68 2 4 8 H 2 2 4 L
F 59 choroid 8.4 14.7 mixed N pT2a 59 59 3 4 12 H 3 3 9 H
F 55 choroid 10.5 16.2 mixed N pT2a 58 58 2 3 6 L 2 3 6 H
F 54 choroid/cil.body 9.76 9.5 mixed N pT2b 58 58 3 4 12 H 0 0 0 L
M 84 choroid/cil.body 11.9 14.8 mixed N pT2b 56 56 2 4 8 H 2 4 8 H
M 73 choroid 9.7 11.3 mixed N pT2a 55 55 3 3 9 H 0 0 0 L
M 76 choroid/cil.body 8.9 13.3 mixed N pT2b 55 55 2 4 8 H 0 0 0 L
F 63 choroid/cil.body 10.3 17.2 spindle N pT2b 54 54 2 4 8 H 1 3 3 L
F 45 choroid 13.7 10.2 mixed N pT2a 50 50 2 4 8 H 3 4 12 H
M 58 choroid 13.1 15.3 spindle N pT2a 49 49 3 3 9 H 2 3 6 H
M 75 choroid 6.1 11.7 mixed N pT2a 41 41 2 4 8 H 3 4 12 H
M 81 choroid 9.2 14.3 spindle N pT2a 39 39 2 4 8 H 2 4 8 H
F 84 choroid 11.7 17.4 mixed N pT3a 30 30 3 4 12 H 2 3 6 H
M 75 choroid 8.8 11.3 mixed N pT2a 73 73 3 3 9 H 1 3 3 L
M 49 choroid/cil.body 13.79 16.6 mixed N pT3b 25 25 2 4 8 H 1 3 3 L
F 51 choroid 9.42 16 mixed N pT3a 24 24 3 4 12 H 2 4 8 H
M 73 choroid 9.24 17.7 epithelioid N pT2a 23 23 2 4 8 H 1 3 3 L
M 62 choroid 13.68 14.7 mixed N pT3a 23 23 2 4 8 H 0 0 0 L
F 85 choroid/cil.body 7.3 12.5 spindle Y pT2d 22 22 3 3 9 H 1 3 3 L
F 66 choroid/cil.body 8.95 15.4 mixed N pT2b 18 18 2 3 6 L 3 4 12 H
M 72 choroid 7.42 10.5 mixed N pT3b 12 12 3 3 9 H 3 4 12 H
F 61 choroid 12.05 12.4 spindle N pT2a 12 12 3 3 9 H 2 3 6 H
M 63 choroid 8.6 10.5 mixed N pT3a 11 11 2 4 8 H 2 4 8 H
F 52 choroid/cil.body 9.5 13.2 mixed N pT2b 9 9 3 4 12 H 2 4 8 H
DFS, disease free survival; RKIP, Raf kinase inhibitor protein; pRKIP, phosphorylated Raf kinase inhibitor protein; cil.body, ciliary body.
between the two groups in RKIP (p<0.001), but not in
pRKIP expression.
Discussion
Approximately 50 percent of patients diagnosed with
an uveal melanoma develop metastasis within 10 to 15
years after enucleation (Collaborative Ocular Melanoma
Study Group, 2001). Once metastasis is diagnosed uveal
melanoma is typically fatal within 1 year because there
are currently no effective treatments. The variables that
are best predictive of poor patient survival are epitheliod
1329
RKIP and uveal melanoma
Table 2. Demographics, tumour parameters, disease free time, follow-up and RKIP and pRKIP expression in primary uveal melanoma with metastasis.
Sex Age Location Thickness Largest Cell Extrascleral Pathological DFS Follow-up RKIP pRKIP
(yrs) (mm) diameter (mm) type extension T stage (months) (months)
IS ES IRS IS ES IRS
F 58 choroid 6.04 17.8 mixed N pT2a 63 64 (†) 0 0 0 L 1 3 3 L
M 71 choroid 13.14 17.1 epithelioid N pT3a 33 34(†) 2 4 8 H 0 0 0 L
F 74 choroid 5.7 12.1 spindle N pT2a 24 37(†) 0 0 0 L 0 0 0 L
F 60 choroid 8.25 16.5 spindle N pT2a 11 37(†) 0 0 0 L 1 3 3 L
F 72 choroid 6.7 15.2 epithelioid N pT2a 14 28(†) 0 0 0 L 0 0 0 L
M 69 choroid 7.21 15.8 mixed N pT2a 54 65 0 0 0 L 2 3 6 H
M 76 choroid 13.7 17.1 mixed N pT2a 14 54 1 2 2 L 2 4 8 H
F 57 choroid/cil.body 13.6 19 mixed N pT2b 6 39 1 1 1 L 3 4 12 H
M 72 choroid/cil.body 13.3 15.4 mixed N pT3b 0 35 2 2 4 L 3 3 9 H
F 50 choroid 7.36 15.6 epithelioid N pT2a 41 65 2 4 8 H 1 3 3 L
F 48 choroid 8.24 14.9 epithelioid N pT3a 1 13(†) 2 1 2 L 1 3 3 L
M 64 choroid 10.7 14.5 epithelioid N pT3a 32 45 1 4 4 L 2 3 6 H
DFS, disease free survival; RKIP, Raf kinase inhibitor protein; pRKIP, phosphorylated Raf kinase inhibitor protein; cil.body, ciliary body. (†) death
Table 3. Median (range) of demographics, tumour parameters, disease free time, follow-up, RKIP and pRKIP expression in primary uveal melanoma
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p (metastasis free vs
metastasis) 0.843* 0.438° 0.287* 0.150* 0.025* 0.601° 0.297* 0.006* 0.361* <0.001 0.798
*: Kolmogorov-Smirnov test. °: chi-square test
Table 4. Number of uveal melanoma (with and without metastasis) with low and high RKIP and pRKIP.
RKIP pRKIP
Metastasis (n=12) Metastasis free (n=32) Metastasis (n=12) Metastatis free (n=32)
Low 10 (83.3%) * 2 (6.3%) 7 (41.7%) ° 15 (46.9%)
High 2 (16.7%) 30 (93.7%) 5 (58.3%) 17 (53.1)
RKIP, Raf kinase inhibitor protein; pRKIP, phosphorylated Raf kinase inhibitor protein. p (chi-square). *: p<0.001. °: p=0.957, ns
cell type, largest tumour dimension, extrascleral
extension, and mitotic activity, followed by vascular
patterns, presence of lymphocytes per 20 high-power
fields, greater tumour pigmentation, and foci of necrosis.
Clinical risk factors for survival are older age and sex of
the patients (prognosis is worse in males).
Cytogenetic testing demonstrates that loss of 1 copy
of chromosome 3 (monosomy 3) is predictive of poor
likelihood of survival (Prescher et al., 1996). Onken
(Onken et al., 2004) found uveal melanomas clustered
into two groups, described as class 1 and class 2. Class 1
lesions were unlikely to undergo metastasis, have better
prognoses and are associated with disomy 3 and a gain
of chromosome 6p; class 2 lesions predicted a greater
rate of metastasis and disease-related mortality, and are
associated with a loss of heterozygosity of chromosome
1330
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Fig. 1. RKIP in uveal
melanoma. a. Mild and diffuse
cytoplasmic positivity in spindle
cell malignant melanoma. 
b. Strong and diffuse
cytoplasmic positivity in spindle
cell malignant melanoma. 
x 200
3. Harbour (Harbour, 2010) recently found inactivating
somatic and germ line mutations of BRCA1 associated
protein-1 (BAP1) in 84% of metastasizing uveal
melanoma lesions. Nevertheless, molecular genetic tests
demonstrate some limitations, such as availability and
costs. The ability to predict the risk of metastatic relapse
is of paramount importance because it may allow the
identification of patients who should be monitored more
frequently and who could benefit from adjuvant
chemotherapy, even if at present there is not a
standardized adjuvant therapy for uveal melanoma. 
RKIP is a promising metastasis repressor that
regulates several physiologic functions. Current
evidence indicates that RKIP also cross-talks with
several important cellular signaling pathways, including
NF-κB (Yeung et al., 2001) and G-proteins (Kroslak et
al., 2001). RKIP also suppressed metastasis in prostate,
breast and ovarian cancer models (Fu et al., 2003; Li et
1331
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Fig. 2. pRKIP in uveal
melanoma. a. Mild and focal
cytoplasmic positivity in
epithelioid cell malignant
melanoma. b. Strong and
diffuse cytoplasmic positivity
in epithelioid cell malignant
melanoma. x 200
al., 2008, 2009). Furthermore, loss of cytoplasmic RKIP
has also been associated with colorectal carcinoma
recurrence and with poor prognosis (Al-Mulla et al.,
2006). In cutaneous nevi, almost all samples showed
strong RKIP immunostaining, whereas RKIP expression
was diminished or completely lost in primary malignant
melanoma and in metastasis (Schuierer et al., 2004). In
cutaneous melanoma, reduced levels of RKIP expression
correlate with metastatic stage (Schuierer et al., 2004;
Park et al., 2005), probably because RKIP acts as
suppressor of metastasis by decreasing vascular
invasion. 
To the best of our knowledge, this is the first time
that RKIP and pRKIP have been characterized in uveal
melanoma. We found that tumour expression of RKIP
was a prognostic factor for risk of metastasis. In our
samples the median value of IRS for RKIP was 8,
corresponding to a moderate staining in more than 75%
of the neoplastic cells, or severe staining in more than
50% of the neoplastic cells. The patients with lower
RKIP expression showed higher incidence of metastasis
after enucleation. At the same time, patients that had a
high level of RKIP expression were significantly less
likely to develop metastasis. This is consistent with the
data reported by Li and colleagues (Li et al., 2008)
which documented that the overexpression of RKIP
suppressed the ability of human ovarian cancer cells to
metastasize when transplanted into nude mice. However,
the molecular mechanism of the antimetastatic function
of RKIP is poorly defined and requires clarification. In
melanoma, Schuierer and colleagues (Schuierer et al.,
2004) showed that RKIP expression is lost in
transformed cells and significant downregulation or
complete extinction of RKIP occurs in melanoma
metastases. They also documented that loss of RKIP
expression in metastasis is not due to genomic loss,
because no alterations of the genomic region of RKIP on
human chromosome 12q23 and its adjacent areas have
been reported for any cancer, supporting the hypothesis
that it is not chromosomal changes, but other alterations
that may lead to dysregulation of RKIP. RKIP has been
reported to inhibit NF-κB activation by several distinct
mechanisms. First, RKIP inhibits NF-κB activation as a
result of its inhibitory effects on Raf-1 by interfering
with MEK phosphorylation and subsequent activation by
Raf-1 (Yeung et al., 2000). Second, RKIP interferes
directly with NF-κB activation by interacting and
blocking NIK and TAK1, which are necessary for NF-
κB activation (Wu and Bonavida, 2009). RKIP can also
inhibit IKKa and IKKb kinase activities in vitro (Wu and
Bonavida, 2009). A potential mechanism underlying this
activity in metastatic melanoma cells could be the cross-
talk between RKIP and the prometastatic protein
melanoma differentiation associated gene-9 (MDA-9),
also known as syntenin, and therefore blocking c-Src
activation and NF-κB activation (Das et al., 2012). As
reported in the literature (Gangemi et al., 2012), the gene
expression profiles of primary human uveal melanomas
showed high expression of the gene encoding for
syntenin in patients with recurrence, and
immunohistochemistry showed that high expression of
MDA-9/syntenin protein in primary tumors was
significantly related to metastatic recurrence. 
We present evidence that the expression levels of
pRKIP were not significantly different between primary
uveal melanoma with metastasis and primary uveal
melanoma without metastasis. Therefore, the level of
pRKIP had no predictive value for uveal melanoma
metastasis. The underlying mechanism of the differential
expression of pRKIP and RKIP is not known. We had
expected that relatively lower levels of pRKIP might
correlate with higher RKIP levels, which would inhibit
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Fig. 3. Kaplan-Meier survival analyses for low and high RKIP expression (left), and low and high pRKIP expression (right). The logrank test showed
significant differences between the two groups in RKIP (p<0.001) but not in pRKIP (p=862, ns).
the Raf-1 and NF-κB pathways and presumably result in
better prognosis. Likewise, we expected relatively higher
levels of pRKIP to correlate with the residual lower level
of active RKIP, resulting in minimal inhibition of
survival pathways, thus resulting in poorer prognosis.
However, interestingly, our present data are not
concordant with these expectations. Nevertheless, we
emphasize the importance of examining the expression
of both the non-phosphorylated active RKIP and
phosphorylated inactive RKIP as already reported in the
literature. 
In conclusion, RKIP expression is a suitable and
easily determinable marker in the primary tumour that
could predict the risk of uveal melanoma to metastasize,
and hence guide strategies for monitoring and therapy.
The relationship between RKIP expression in primary
tumours and metastatic relapse and overall survival
gains in significance given the lack of effective markers
of metastatic risk. A simple test such as RKIP expression
in the primary tumour could provide an economically
viable and immediately available decision aid. A
limitation of the current study is the paucity of
specimens available for evaluation. This is due to
changes in the clinical management of uveal melanomas,
many of which are treated with brachytherapy or proton
beam radiotherapy rather than undergoing enucleation.
Thus, while these preliminary results point to an
association between low expression of RKIP and the
development of metastasis, further studies with larger
series are needed to validate RKIP expression as a
prognostic marker in uveal melanoma. Given that fine-
needle aspiration biopsy (FNAB) of uveal melanoma is
becoming more commonplace, it will also be interesting
in future to assess the expression levels of RKIP in the
biopsies of uveal melanoma.
This study did not address the relationship between
RKIP expression and patients’ response to
chemotherapy. An evaluation of RKIP expression in
melanoma metastasis could be of interest given the
recent data showing that chemotherapeutic drug
treatments induce RKIP expression, which in turn
sensitizes tumoural cells to apoptosis (Chatterjee et al.,
2004).
References
Akaishi J., Onda M., Asaka S., Okamoto J., Miyamoto S., Nagahama
M., Ito K., Kawanami O. and Shimizu K. (2006). Growth suppressive
function of phosphatidylethanolamine-binding protein in anaplastic
thyroid cancer. Anticancer Res. 26, 4437-4442.
Al-Mulla F., Hagan S., Behbehani A.I., Bitar M.S., George S.S., Going
J.J., García J.J., Scott L., Fyfe N., Murray G.I. and Kolch W. (2006).
Raf kinase inhibitor protein expression in a survival analysis of
colorectal cancer patients. J. Clin. Oncol. 24, 5672-5679. 
Al-Mulla F., Bitar M.S., Taqi Z., Rath O. and Kolch W. (2010). RAF
kinase inhibitory protein (RKIP) modulates cell cycle kinetics and
motility. Mol. Biosyst. 7, 928-941.
Allegra E., Caltabiano R., Amorosi A., Vasquez E., Garozzo A. and
Puzzo L. (2013). Expression of BMI1 and p16 in laryngeal
squamous cell carcinoma. Head Neck 35, 847-851. 
Baritaki S., Chapman A., Yeung K., Spandidos D.A., Palladino M. and
Bonavida B. (2009). Inhibition of epithelial to mesenchymal transition
in metastatic prostate cancer cells by the novel proteasome inhibitor,
NPI-0052: pivotal roles of Snail repression and RKIP induction.
Oncogene 28, 3573-3585. 
Buzzacco D.M., Abdel-Rahman M.H., Park S., Davidorf F., Olencki T.
and Cebulla C.M. (2012). Long-term survivors with metastatic uveal
melanoma. Open Ophthalmol. J. 6, 49-53. 
Chatterjee D., Bai Y., Wang Z., Beach S., Mott S., Roy R., Braastad C.,
Sun Y., Mukhopadhyay A., Aggarwal B.B., Darnowski J., Pantazis
P., Wyche J., Fu Z., Kitagwa Y., Keller E.T., Sedivy J.M. and Yeung
K.C. (2004). RKIP sensitizes prostate and breast cancer cells to
drug induced apoptosis. J. Biol. Chem. 279, 17515-17523. 
Collaborative Ocular Melanoma Study Group. (2001). Assessment of
metastatic disease status at death in 435 patients with large
choroidal melanoma in the Collaborative Ocular Melanoma Study
(COMS): COMS report no. 15 Arch. Ophthalmol. 119, 670-676. 
Corbit K.C., Trakul N., Eves E.M., Diaz B., Marshall M. and Rosner M.R.
(2003). Activation of Raf-1 signaling by protein kinase C through a
mechanism involving Raf kinase inhibitory protein. J. Biol.Chem.
278, 13061-13068. 
Das S.K., Bhutia S.K., Sokhi U.K., Azab B., Su Z.Z., Boukerche H.,
Anwar T., Moen E.L., Chatterjee D., Pellecchia M., Sarkar D. and
Fisher P.B. (2012). Raf kinase inhibitor RKIP inhibits MDA-
9/syntenin-mediated metastasis in melanoma. Cancer Res. 72,
6217-6226.
Fu Z., Smith P.C., Zhang L., Rubin M.A., Dunn R.L., Yao Z. and Keller
E.T. (2003). Effects of raf kinase inhibitor protein expression on
suppression of prostate cancer metastasis. J. Natl. Cancer. Inst. 95,
878-889. 
Gangemi R., Mirisola V., Barisione G., Fabbi M., Brizzolara A., Lanza F.,
Mosci C., Salvi S., Gualco M., Truini M., Angelini G., Boccardo S.,
Cilli M., Airoldi I., Queirolo P., Jager M.J., Daga A., Pfeffer U. and
Ferrini S. (2012). Mda-9/syntenin is expressed in uveal melanoma
and correlates with metastatic progression. PLoS One 7, e29989. 
Greten F.R. and Karin M. (2004). The IKK/NF-kappaB activation
pathway: A target for prevention and treatment of cancer. Cancer
Lett. 206, 193-199.
Harbour J.W., Onken M.D., Roberson E.D., Duan S., Cao L., Worley
L.A., Council M.L., Matatall K.A., Helms C. and Bowcock A.M.
(2010). Frequent mutation of BAP1 in metastasizing uveal
melanomas. Science 330, 1410-1413.
Hellmann J., Rommelspacher H., Muhlbauer E. and Wernicke C. (2010).
Raf kinase inhibitor protein enhances neuronal differentiation in
human SH-SY5Y cells. Dev. Neurosci. 32, 33-46.
Kroslak T., Koch T., Kahl E. and Hollt V. (2001). Human
phosphatidylethanolaminebinding protein facilitates heterotrimeric G
protein-dependent signaling. J. Biol. Chem. 276, 39772-39778. 
Leonardi R., Loreto C., Talic N., Caltabiano R. and Musumeci G. (2012).
Immunolocalization of lubricin in the rat periodontal ligament during
experimental tooth movement. Acta Histochem. 114, 700-704. 
Li H.Z., Wang Y., Gao Y., Shao J., Zhao X.L., Deng W.M., Liu Y.X.,
Yang J. and Yao Z. (2008). Effects of raf kinase inhibitor protein
expression on metastasis and progression of human epithelial
ovarian cancer. Mol. Cancer Res. 6, 917-928. 
Li H.Z., Gao Y., Zhao X.L., Liu Y.X., Sun B.C., Yang J. and Yao Z.
(2009). Effects of raf kinase inhibitor protein expression on
metastasis and progression of human breast cancer. Mol. Cancer
1333
RKIP and uveal melanoma
Res. 7, 832-840. 
Lorenz K., Lohse M.J. and Quitterer U. (2003). Protein kinase C
switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426,
574-579. 
Margo C.E. and McLean I.W. (1984). Malignant melanoma of the
choroid and ciliary body in black patients. Arch. Ophthalmol. 102,
77-79. 
McLean I.W., Foster W.D., Zimmerman L.E. and Gamel J.W. (1983).
Modifications of Callender's classification of uveal melanoma at the
Armed Forces Institute of Pathology. Am. J. Ophthalmol. 96, 502-
509. 
Onken M.D., Worley L.A., Ehlers J.P. and Harbour J.W. (2004). Gene
expression profiling in uveal melanoma reveals two molecular
classes and predicts metastatic death. Cancer Res. 64, 7205-
7209. 
Park S., Yeung M.L., Beach S., Shields J.M. and Yeung K.C. (2005).
RKIP downregulates B-Raf kinase activity in melanoma cancer cells.
Oncogene 24, 3535-3540. 
Prescher G., Bornfeld N., Hirche H., Horsthemke B., Jöckel K.H. and
Becher R. (1996). Prognostic implications of monosomy 3 in uveal
melanoma. Lancet 347, 1222-1225. 
Reddy K.B., Nabha S.M. and Atanaskova N. (2003). Role of MAP
kinase in tumour progression and invasion. Cancer Metastasis Rev.
22, 395-403. 
Schuierer M.M., Bataille F., Hagan S., Kolch W. and Bosserhoff A.K.
(2004). Reduction in Raf kinase inhibitor protein expression is
associated with increased Ras-extracellular signal-regulated kinase
signaling in melanoma cell lines. Cancer Res. 64, 5186-5192. 
Serre L., Pereira de Jesus K., Zelwer C., Bureaud N., Schoentgen F.
and Benedetti H. (2001). Crystal structures of YBHB and YBCL form
Escherichia coli, two bacterial homologues to a Raf kinase inhibitor
protein. J. Mol. Biol. 310, 617-634. 
Shah C.P., Weis E., Lajous M., Shields J.A. and Shields C.L. (2005).
Intermittent and chronic ultraviolet light exposure and uveal
melanoma: a meta-analysis. Ophthalmology. 112, 1599-1607.
Singh A.D. and Topham A. (2003). Survival rates with uveal melanoma
in the United States: 1973-1997. Ophthalmology 110, 962-965.
Spagnolo F., Caltabiano G. and Queirolo P. (2012). Uveal melanoma.
Cancer Treat. Rev. 38, 549-553.
Wu K. and Bonavida B. (2009). The activated NF-kappaB-Snail-RKIP
circuitry in cancer regulates both the metastatic cascade and
resistance to apoptosis by cytotoxic drugs. Crit. Rev. Immunol. 29,
241-254.
Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F.,
Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M. and Kolch W.
(1999). Suppression of Raf-1 kinase activity and MAP kinase
signalling by RKIP. Nature 401, 173-177. 
Yeung K., Janosch P., McFerran B., Rose D.W., Mischak H., Sedivy
J.M. and Kolch W. (2000). Mechanism of suppression of the
Raf/MEK/extracellular signalregulated kinase pathway by the raf
kinase inhibitor protein. Mol. Cell. Biol. 20, 3079-3085.
Yeung K.C., Rose D.W., Dhillon A.S., Yaros D., Gustafsson M.,
Chatterjee D., Mc Ferran B., Wyche J., Kolch W. and Sedivy J.M.
(2001). Raf kinase inhibitor protein interacts with NF-kappaB-
inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol.
Cell. Biol. 21, 7207-7217. 
Accepted April 24, 2014
1334
RKIP and uveal melanoma
